Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_1
3
50%
Ph phase_2
2
33%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

NCT02365506
completedphase_1

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

NCT02412098
completedphase_2

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

NCT02104583
terminatedphase_2

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
terminatedphase_3

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

NCT02300558
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02365506Phase 1

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

Completed
NCT02412098Phase 1

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Completed
NCT02104583Phase 2

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Completed
NCT02291237Phase 2

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Terminated
NCT02300558Phase 3

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Terminated
NCT02441829Phase 1

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6